Ombitasvir, Paritaprevir Co-dosed with Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected with HIV-1 a Randomized Trial

JAMA - Journal of the American Medical Association

Volumn 313, Issue 12, 2014, Pages 1223-1231

  Sulkowski, Mark S ^a   Eron, Oseph J ^b   Wyles, David ^c   Trinh, Roger ^d   Lalezari, Jay ^e   Wang, Chia ^f   Slim, Jihad ^g   Bhatti, Laveeza ^h   Gathe, Joseph ⁱ   Ruane, Peter J ^j   Elion, Richard ^k   Bredeek, Fritz ^l   Brennan, Robert ^m   Blick, Gary ⁿ   Khatri, Amit ^d   Gibbons, Krystal ^d   Hu, Yiran B ^d   Fredrick, Linda ^d   Schnell, Gretja ^d   Pilot Matias, Tami ^d   Tripathi, Rakesh ^d   Da Silva Tillmann, Barbara ^d   McGovern, Barbara ^d   Campbell, Andrew L ^d   Podsadecki, Thomas ^c   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ABBVIE INC   (United States)

^e Quest Clinical Research   (United States)

^f VIRGINIA MASON MEDICAL CENTER   (United States)

^g ST MICHAEL S MEDICAL CENTER   (United States)

^h AIDS HEALTHCARE FOUNDATION   (United States)

ⁱ Cure C Consortium   (United States)

^j Ruane Medical and Liver Health Institute   (United States)

^k Whitman Walker Health   (United States)

^l Metropolis Medical   (United States)

^m Medical Assoc of Central Virginia   (United States)

ⁿ Circle Care Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CD4 ANTIGEN; DASABUVIR; INTERLEUKIN 28B; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; VIRUS RNA; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; SULFONAMIDE; URACIL;

ADULT; AGED; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; EYE JAUNDICE; FATIGUE; FEMALE; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; INSOMNIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIXED INFECTION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYLOGENY; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; PUERTO RICO; RANDOMIZED CONTROLLED TRIAL; REINFECTION; RELAPSE; TOOTH ABSCESS; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED;

ADULT; ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; PILOT PROJECTS; RIBAVIRIN; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; URACIL;

EID: 84925428093     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.1328     Document Type: Article

References (32)

1. Sulkowski MS. HCV therapy in HIV-infected patients. Liver Int. 2013;33(suppl 1):63-67.
2. Kitahata MM, Gange SJ, Abraham AG, et al NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815-1826.
3. Lo Re V III, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014;160(6):369-379.
4. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: ameta-analysis. Clin Infect Dis. 2001;33(4):562-569.
5. Soto B, Sánchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26(1):1-5.
6. Rodriguez-Torres M, Slim J, Bhatti L, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials. 2012;13(3):142-152.
7. Puoti M, Rossotti R, Travi G, et al. Optimizing treatment in HIV/HCV coinfection. Dig Liver Dis. 2013;45(suppl 5):S355-S362.
8. Sulkowski M, Pol S, Mallolas J, et al; P05411 study investigators. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13(7):597-605.
9. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86-96.
10. Rodriguez-Torres M, Rodriguez-Orengo J, Gaggar A, et al. Sofosbuvir and peginterferon alfa-2a/ribavirin for treatment-naive genotype 1-4 HCV-infected patients who are coinfected with HIV. Poster presented at: IDWeek; October 2-6, 2013; San Francisco, CA.
11. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl JMed. 2014;370(17):1594-1603.
12. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604-1614.
13. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973-1982.
14. Ferenci P, Bernstein D, Lalezari J, et al PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983-1992.
15. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97%and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359-365.e1.
16. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA. 2012;308(4):370-378.
17. th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 6, 2014;Washington, DC.
18. th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 6, 2014; Washington, DC.
19. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286(2):171-179.
20. Sklar PA, Ward DJ, Baker RK, et al HIV Outpatient Study (HOPS) Investigators. Prevalence and clinical correlates of HIV viremia ("blips") in patients with previous suppression below the limits of quantification. AIDS. 2002;16(15):2035-2041.
21. Zhang S, van Sighem A, Gras L, et al. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment. Antivir Ther. 2010;15(4):555-562.
22. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al APRICOT Study Group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438-450.
23. Sulkowski MS, Naggie S, Lalezari J, et al; PHOTON-1 Investigators. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312(4):353-361.
24. Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology. 2012;55(3):749-758.
25. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6):1918-1929.
26. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997;26(2):473-477.
27. Rodríguez Nóvoa S, Barreiro P, Rendón A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis. 2006;42(2):291-295.
28. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study [published online February 3, 2015]. Lancet. doi:10.1016/S0140-6736(14)62483-1.
29. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial [published online November 11, 2014]. Lancet. doi:10.1016/S0140-6736(14)61793-1.
30. Martin TC, Martin NK, Hickman M, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS. 2013;27(16):2551-2557.
31. Afdhal N, Reddy KR, Nelson DR, et al; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493.
32. th Annual Scientific Meeting; October 20, 2014; Philadelphia, PA.